Global Recognition For
Aanjaneya Lifecare, Enters The Elite List of Golden Peacock Awards, Receives “Golden
Peacock National Quality Award’
Aanjaneya Lifecare
Selected in Pharmaceutical Sector For Robust Growth, Corporate Governance &
Innovative Business Approach in tough Market Conditions.
India. Maharashtra,
Mumbai, Saturday, 9th Feb 2013. Mumbai-based
Aanjaneya Lifecare Limited BSE code
(533412), the vertically integrated pharmaceutical company with
manufacturing and marketing capabilities in APIs (Active Pharmaceutical
Ingredients) with focus on anti-malarial, and finished dosage forms (FDFs)
catering to various therapeutic segments, has received yet another feather in its cap at Golden Peacock National Quality Award – 2012 by winning the coveted
title in Bangalore on 8th Feb 2013 in the presence of distinguished
gathering of business leaders, jurists, academics, environmentalists,
economists, legislators and policy makers during the 23rd World Congress on
Leadership and Quality of Governance,. Aanjaneya Lifecare Ltd' has been
selected as the winner of the ‘Golden
Peacock National Quality Award’ on
account of its formidable growth momentum under tough business environment for
the year 2012 by the Awards Jury under the Chairmanship of Justice P. N. Bhagwati,
former Chief Justice of India and Member, UN Human Rights Commission, Justice M N Venkatachaliah, chairman,
IOD Advisory Council & former Chief Justice of India were among the judging
panel for this year's Golden Peacock Awards. BRAND image was among the most
important criteria in the selection process. The Prestigious Award was
conferred at a glittering award evening by Justice M N Venkatachaliah, Former Chief Justice of India at a power packed
audience at Hotel Lalit Ashoka, Bangalore. The Coveted Award was received by Mr Kashi Vishwanath, Chairman of
Aanjaneya Lifecare Ltd.
On Friday, Aanjaneya declared the First 9 months report card
where The
Net Profit of Aanjaneya Lifecare Limited rose 8.19% to Rs 387.22 million in the
first nine months ended 31st December 2012 as against Rs 357.91 million during
the corresponding period of the last year. Total Sales during the first nine
months ended 31st December 2012 was up 40.16% at Rs 4468.46 million
as against Rs 3188.12 million for the same period last year.
Speaking on the Award, Dr Kannan
Vishwanath, Vice-Chairman & Managing Director, Aanjaneya Lifecare Ltd said
“ This
coveted title of Golden Peacock National Quality Awards reflect the resounding
success of Aanjaneya Lifecare in the Pharmaceutical Industry in a short span of
time & meeting the tough global challenges of keeping the winning Momentum,
This Award is a standing testimony of the entire Aanjaneya Lifecare’s internal
& external stakeholders who have reposed faith in our Organization”. While we are elated to receive this rare
distinction, our responsibility increases manifold as the road ahead are full
of challenges & plethora of opportunities Dr Kannan added. The award is a
validation for our innovative tool used to predict results and plan results
with appropriate action plans is Scientific, Logical and well accepted and
rightly acknowledged by a reputed team of assessors and distinguished
Jury.". The
Golden Peacock Awards were initiated by Institute of Directors, an apex
association of Directors, in 1991. The Golden Peacock Awards Secretariat
receives over 1000 entries each year for various awards, from over 25 countries
worldwide. The Golden Peacock Awards is a set of prestigious national and
global awards designed to improve productivity and quality in organizations.
About Aanjaneya
Lifecare Limited:
Aanjaneya Lifecare Limited is a vertically integrated company
having state-of-the-art; WHO GMP approved facilities for manufacturing bulk
drugs at Mahad and finished dosage forms at Pirungut near Pune. It is one of
the largest contract manufacturers of codeine based cough syrups in India. The
company exclusively manufactures the Codorex Brand of Zydus Cadilla and
Codilite Brand of Tablets India Ltd. amongst others.The company raised about
Rs. 117 crore from its IPO and the funds are being used to built new capacities
along with the refurbishing of Research & Development centre. The new
facilities being created as part of CAPEX are using eco friendly, recyclable
material and will be rated by LEEDS once completed.The Facilities being
established will comply with the latest European & US guidelines. With new
capacities to be added in next 6 to 9 months the company will be expanding
operations in emerging markets of South East Asia, Africa & South &
Central America and its domestic operation in branded generics segment.
The company with its manufacturing
facilities –in Mahad, Hyderabad and Pune has to its credit many achievements.
Ø It is the world’s third-largest manufacturer of quinine salts in the
world . Only nine companies globally manufacture quinine salts.
Ø One of the largest codeine based formlulations manufacturer in the
pharmaceutical sector
Ø One of the largest manufacturer of multi- flavored Lozenges in medical products in
India
Ø The company pioneered the recognition that lozenges represent a stable
platform for the delivery of pharmaceutical and nutraceutical ingredients
Ø Anjaneya’s Nicco Nil lozenge is a first-of-its-kind hard boiled
lozenge remedy for smoking de-addition; its Relacs is a first-time lozenge
against insomnia and Arecta Plus, a lozenge variant for Erectile Dysfunction,
is a first of its kind .
The
company has an expertise in opportunity spotting and innovation. The company’s
success has been built on a business model that integrates Research, Innovation
and Knowledge. The company has invested in building proprietary Knowledge
through research and acquisitions. Anajaneyas Lifecare’s competence has been
validated through patents granted by international and Indian authorities.
Highlights 2011-2012 for Active Pharmaceutical
Ingredents
Ø
Production of Quinine Sulphate
increased 30% in 2011-2012
Ø
Sales of Quinine Sulphate grew 45%
Ø
Exports increased 250% from Rs 10
Crore to Rs 31 crore
Ø
Added 35 international and 50 domestic
clients
Ø
Completed trials for
Bromexine(expectorant)a new API that will be launched in 2012-1023
Highlights 2011-2012 for Finished
Dosage Forms
Ø
Launched 'Rancorex' an in-house codine
based cough syrup brand for the first time in its history
Ø
received the Kenya PPB GMP approval
from all facilities namely lozenges,liquids and iontments
Ø
Received registration for 'Arecta
Plus'(a lozenge variant of Viagra tablets)from Sierrs Leone and Libya; received
the first export order for this product to be executed in 2012-2013.
Ind
